|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.48 USD | +1.21% |
|
-1.31% | -38.34% |
| Dec. 02 | Moderna, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-02-2025 11:00 AM | |
| Dec. 01 | Trading Day: World shivers on Japan rate chill | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
Return on Assets | -10.69 | 51.93 | 23.3 | -11.97 | -15.14 | ||||
Return on Total Capital | -23.21 | 93.06 | 33.28 | -14.96 | -18.44 | ||||
Return On Equity % | -39.99 | 146.08 | 50.27 | -28.59 | -28.77 | ||||
Return on Common Equity | -39.99 | 146.08 | 50.27 | -28.59 | -28.77 | ||||
Margin Analysis | |||||||||
Gross Profit Margin % | -71.56 | 75.05 | 54.78 | -39.28 | -85.63 | ||||
SG&A Margin | 23.43 | 3.07 | 5.88 | 22.62 | 36.28 | ||||
EBITDA Margin % | -91.1 | 73.24 | 50.71 | -52.83 | -116.07 | ||||
EBITA Margin % | -94.99 | 71.98 | 48.9 | -61.9 | -121.91 | ||||
EBIT Margin % | -94.99 | 71.98 | 48.9 | -61.9 | -121.91 | ||||
Income From Continuing Operations Margin % | -92.99 | 66.06 | 43.41 | -68.84 | -110.04 | ||||
Net Income Margin % | -92.99 | 66.06 | 43.41 | -68.84 | -110.04 | ||||
Net Avail. For Common Margin % | -92.99 | 66.06 | 43.41 | -68.84 | -110.04 | ||||
Normalized Net Income Margin | -58 | 44.95 | 31.13 | -35.32 | -68.58 | ||||
Levered Free Cash Flow Margin | 272.65 | 50.31 | 19.04 | -34.8 | -95.41 | ||||
Unlevered Free Cash Flow Margin | 273.42 | 50.37 | 19.14 | -34.45 | -94.95 | ||||
Asset Turnover | |||||||||
Asset Turnover | 0.18 | 1.15 | 0.76 | 0.31 | 0.2 | ||||
Fixed Assets Turnover | 2.38 | 20.87 | 10.94 | 2.86 | 1.15 | ||||
Receivables Turnover (Average Receivables) | 1.15 | 8.09 | 8.45 | 5.86 | 4.97 | ||||
Inventory Turnover (Average Inventory) | - | 6.19 | 6.02 | 13.27 | 37.66 | ||||
Short Term Liquidity | |||||||||
Current Ratio | 1.43 | 1.76 | 2.73 | 3.42 | 3.67 | ||||
Quick Ratio | 1.37 | 1.54 | 2.34 | 3.21 | 3.45 | ||||
Operating Cash Flow to Current Liabilities | 0.46 | 1.49 | 1.01 | -1.03 | -1.36 | ||||
Days Sales Outstanding (Average Receivables) | 317.97 | 45.11 | 43.2 | 62.29 | 73.58 | ||||
Days Outstanding Inventory (Average Inventory) | - | 58.93 | 60.67 | 27.51 | 9.72 | ||||
Average Days Payable Outstanding | - | 9.73 | 17.67 | 21.27 | 28.58 | ||||
Cash Conversion Cycle (Average Days) | - | 94.32 | 86.21 | 68.54 | 54.71 | ||||
Long Term Solvency | |||||||||
Total Debt/Equity | 9.28 | 6.48 | 6.28 | 8.97 | 6.85 | ||||
Total Debt / Total Capital | 8.49 | 6.08 | 5.9 | 8.23 | 6.41 | ||||
LT Debt/Equity | 8.09 | 4.98 | 5.25 | 8.79 | 6.51 | ||||
Long-Term Debt / Total Capital | 7.41 | 4.68 | 4.94 | 8.07 | 6.1 | ||||
Total Liabilities / Total Assets | 65.09 | 42.66 | 26.05 | 24.81 | 22.92 | ||||
EBIT / Interest Expense | -77.19 | 738.67 | 324.83 | -111.55 | -164.38 | ||||
EBITDA / Interest Expense | -70.44 | 761.17 | 344.17 | -89.87 | -149.92 | ||||
(EBITDA - Capex) / Interest Expense | -77.27 | 745.39 | 330.38 | -108.47 | -193.71 | ||||
Total Debt / EBITDA | -0.34 | 0.07 | 0.12 | -0.36 | -0.21 | ||||
Net Debt / EBITDA | 6.28 | -1.22 | -1.71 | 3.53 | 2.44 | ||||
Total Debt / (EBITDA - Capex) | -0.31 | 0.07 | 0.13 | -0.3 | -0.16 | ||||
Net Debt / (EBITDA - Capex) | 5.72 | -1.24 | -1.78 | 2.92 | 1.89 | ||||
Growth Over Prior Year | |||||||||
Total Revenues, 1 Yr. Growth % | 1.23K | 2.2K | 4.29 | -64.45 | -52.75 | ||||
Gross Profit, 1 Yr. Growth % | 31.82 | -2.51K | -23.88 | -125.49 | 3.01 | ||||
EBITDA, 1 Yr. Growth % | 42.2 | -1.95K | -27.79 | -137.04 | 3.81 | ||||
EBITA, 1 Yr. Growth % | 39.84 | -1.84K | -29.15 | -145 | -6.94 | ||||
EBIT, 1 Yr. Growth % | 39.84 | -1.84K | -29.15 | -145 | -6.94 | ||||
Earnings From Cont. Operations, 1 Yr. Growth % | 45.34 | -1.73K | -31.47 | -156.37 | -24.46 | ||||
Net Income, 1 Yr. Growth % | 45.34 | -1.73K | -31.47 | -156.37 | -24.46 | ||||
Normalized Net Income, 1 Yr. Growth % | 44.85 | -1.88K | -27.77 | -140.33 | -8.24 | ||||
Diluted EPS Before Extra, 1 Yr. Growth % | 26.08 | -1.54K | -28.88 | -161.33 | -24.8 | ||||
Accounts Receivable, 1 Yr. Growth % | 25.8K | 128.25 | -56.38 | -35.6 | -59.87 | ||||
Inventory, 1 Yr. Growth % | - | 2.97K | -32.41 | -76.88 | -42.08 | ||||
Net Property, Plant and Equip., 1 Yr. Growth % | 34.45 | 257.36 | 54.66 | 24.26 | 11.17 | ||||
Total Assets, 1 Yr. Growth % | 361.6 | 236.23 | 4.82 | -28.74 | -23.25 | ||||
Tangible Book Value, 1 Yr. Growth % | 118.02 | 452.32 | 35.19 | -28.06 | -21.43 | ||||
Common Equity, 1 Yr. Growth % | 118.02 | 452.32 | 35.19 | -27.55 | -21.32 | ||||
Cash From Operations, 1 Yr. Growth % | -541.64 | 571.93 | -63.43 | -162.6 | -3.66 | ||||
Capital Expenditures, 1 Yr. Growth % | 113.75 | 317.65 | 40.84 | 76.75 | 48.66 | ||||
Levered Free Cash Flow, 1 Yr. Growth % | -759.55 | 324.3 | -60.53 | -164.95 | 29.56 | ||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -769.75 | 323.6 | -60.38 | -163.98 | 30.23 | ||||
Compound Annual Growth Rate Over Two Years | |||||||||
Total Revenues, 2 Yr. CAGR % | 143.89 | 1.65K | 389.78 | -39.11 | -59.01 | ||||
Gross Profit, 2 Yr. CAGR % | 34.24 | 463.88 | 328.38 | -55.95 | -48.76 | ||||
EBITDA, 2 Yr. CAGR % | 37.27 | 412.52 | 265.3 | -48.28 | -37.99 | ||||
EBITA, 2 Yr. CAGR % | 35.89 | 393.47 | 251.37 | -43.54 | -35.29 | ||||
EBIT, 2 Yr. CAGR % | 35.89 | 393.47 | 251.37 | -43.54 | -35.29 | ||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 39.35 | 387.23 | 234.58 | -37.84 | -34.74 | ||||
Net Income, 2 Yr. CAGR % | 39.35 | 387.23 | 234.58 | -37.84 | -34.74 | ||||
Normalized Net Income, 2 Yr. CAGR % | 38.17 | 407.88 | 259.12 | -46.03 | -39.1 | ||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -37.12 | 326.82 | 220.34 | -33.95 | -32.09 | ||||
Accounts Receivable, 2 Yr. CAGR % | 951.16 | 2.33K | -0.22 | -47 | -49.16 | ||||
Inventory, 2 Yr. CAGR % | - | - | 398.51 | -60.47 | -68.35 | ||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 35.13 | 119.17 | 135.1 | 38.63 | 17.54 | ||||
Total Assets, 2 Yr. CAGR % | 93.37 | 293.96 | 87.73 | -13.57 | -26.05 | ||||
Tangible Book Value, 2 Yr. CAGR % | 29.38 | 246.99 | 173.26 | -1.38 | -24.82 | ||||
Common Equity, 2 Yr. CAGR % | 29.38 | 246.99 | 173.26 | -1.03 | -24.5 | ||||
Cash From Operations, 2 Yr. CAGR % | 147.51 | 444.73 | 56.76 | -52.15 | -22.34 | ||||
Capital Expenditures, 2 Yr. CAGR % | -20.14 | 197.91 | 142.54 | 57.78 | 62.1 | ||||
Levered Free Cash Flow, 2 Yr. CAGR % | 195.06 | 431.67 | 29.42 | -49.36 | -8.26 | ||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 196.62 | 431.99 | 29.55 | -49.64 | -8.7 | ||||
Compound Annual Growth Rate Over Three Years | |||||||||
Total Revenues, 3 Yr. CAGR % | 57.45 | 415.2 | 584.74 | 104.31 | -44.04 | ||||
Gross Profit, 3 Yr. CAGR % | 41.1 | 251.57 | 189.26 | 67.25 | -41.53 | ||||
EBITDA, 3 Yr. CAGR % | 43.28 | 226.58 | 166.69 | 70.34 | -34.76 | ||||
EBITA, 3 Yr. CAGR % | 41.5 | 218.05 | 158.4 | 77.11 | -33.3 | ||||
EBIT, 3 Yr. CAGR % | 41.5 | 218.05 | 158.4 | 77.11 | -33.3 | ||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 42.92 | 216.54 | 153.39 | 84.79 | -33.67 | ||||
Net Income, 3 Yr. CAGR % | 42.92 | 216.54 | 153.39 | 84.79 | -33.67 | ||||
Normalized Net Income, 3 Yr. CAGR % | 43.01 | 224 | 165.1 | 73.27 | -35.58 | ||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -22.35 | 78.74 | 134.87 | 84.63 | -31.03 | ||||
Accounts Receivable, 3 Yr. CAGR % | 369.73 | 531.87 | 536.58 | -13.77 | -51.69 | ||||
Inventory, 3 Yr. CAGR % | - | - | - | 79.1 | -59.24 | ||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 40.68 | 86.86 | 95.13 | 90.09 | 28.8 | ||||
Total Assets, 3 Yr. CAGR % | 89.13 | 132.53 | 153.39 | 35.93 | -16.93 | ||||
Tangible Book Value, 3 Yr. CAGR % | 66.86 | 109.87 | 153.43 | 75.14 | -8.58 | ||||
Common Equity, 3 Yr. CAGR % | 66.86 | 109.87 | 153.43 | 75.54 | -8.32 | ||||
Cash From Operations, 3 Yr. CAGR % | 82.86 | 245.28 | 121.4 | 15.44 | -39.58 | ||||
Capital Expenditures, 3 Yr. CAGR % | 4.92 | 38.99 | 132.08 | 118.26 | 54.68 | ||||
Levered Free Cash Flow, 3 Yr. CAGR % | 152.69 | 233.02 | 123.46 | 2.85 | -30.74 | ||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 152.98 | 234.01 | 123.83 | 2.41 | -30.88 | ||||
Compound Annual Growth Rate Over Five Years | |||||||||
Total Revenues, 5 Yr. CAGR % | - | 179.44 | 147.88 | 119.28 | 122.01 | ||||
Gross Profit, 5 Yr. CAGR % | - | 142.2 | 120.02 | 53.18 | 44.75 | ||||
EBITDA, 5 Yr. CAGR % | - | 130.34 | 108.35 | 56.26 | 48.79 | ||||
EBITA, 5 Yr. CAGR % | - | 126.35 | 103.58 | 59.3 | 48.52 | ||||
EBIT, 5 Yr. CAGR % | - | 126.35 | 103.58 | 59.3 | 48.52 | ||||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | 124.03 | 100.84 | 65.06 | 47.27 | ||||
Net Income, 5 Yr. CAGR % | - | 124.03 | 100.84 | 65.06 | 47.27 | ||||
Normalized Net Income, 5 Yr. CAGR % | - | 128.6 | 106.6 | 58.2 | 47.13 | ||||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | 49.47 | 36.9 | 20.02 | 42.98 | ||||
Accounts Receivable, 5 Yr. CAGR % | - | 197.94 | 152.79 | 134.48 | 131.63 | ||||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | 76.3 | 72.75 | 65.83 | 59.32 | ||||
Total Assets, 5 Yr. CAGR % | - | 77.07 | 88.57 | 56.51 | 54.83 | ||||
Tangible Book Value, 5 Yr. CAGR % | - | 111.43 | 103.25 | 55.15 | 55.87 | ||||
Common Equity, 5 Yr. CAGR % | - | 111.43 | 103.25 | 55.37 | 56.13 | ||||
Cash From Operations, 5 Yr. CAGR % | - | 189.71 | 71.94 | 56.62 | 45.61 | ||||
Capital Expenditures, 5 Yr. CAGR % | - | 53.67 | 46.94 | 46.22 | 101.04 | ||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | 93.35 | 56.78 | 56.51 | ||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | 93.56 | 56.71 | 56.36 |
- Stock Market
- Equities
- MRNA Stock
- Financials Moderna, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















